MedTrace Logo

PSTC100 Study in Healthy Adult Subjects

NCT07752472 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-08-07

No results posted yet for this study

Summary

This study is a single-center, randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic (PD) characteristics of PSTC100 in healthy adult subjects.

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

PSTC100 tablets

PSTC100 tablets: 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg

DRUG

PSTC100 tablets

100 mg once daily, 200 mg once daily, 300 mg once daily

Sponsors & Collaborators

  • Prospect Therapeutics (Nanjing) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-07
Primary Completion
2027-07-12
Completion
2027-10-10

Countries

  • Australia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07752472 on ClinicalTrials.gov